Over half of the patients diagnosed with HCC have aberrant EGFR/HER3 activation and over-expression of EGFR and its ligands (particularly the dual regulated ligands), which suppress the antitumor capacity of sorafenib. Here, ERBB3 is linked to hepatocellular carcinoma.